Short Course Radical Cure of P. Vivax Malaria in Nepal

Phase 4 Completed 27 enrolled Menzies School of Health Research Tribhuvan University, Nepal · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed as a multicentre randomized, open label trial to assess the safety and efficacy of a low dose short course PQ treatment (3.5mg/kg total dose given over 7 days) in glucose-6-phosphate dehydrogenase (G6PD) normal patients with P.vivax and P falciparum to reduce the risk of subsequent P.vivax episodes.

Timeline

Start: 2021-10-27
Primary completion: 2024-03-31
Completion: 2024-03-31

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper Although the small sample size limits conclusions about efficacy PMID 42033147 ↗

Publications

Ghimire P, Dahal G, Adhikari N, Rijal KR, Adhikari S, Banjara MR, Mnjala H, Lee G, Weston S, Rumaseb A, Rai A, Ley B, Hossain MS, Simpson JA, Rajasekhar M, Adhikari B, Price RN, Lal BK, Thriemer K. Short-Course Low-Dose Primaquine for Radical Cure in G6PD-Normal Patients in the Pre-Elimination Context of Nepal. Trop Med Int Health. 2026 Apr 25. doi: 10.1111/tmi.70145. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Primaquine	Small molecule	0.5 mg/kg	—